全膝关节置换术中胰高血糖素样肽-1受体激动剂使用的趋势、人口学特征与结局:11年视角
该回顾性研究分析2012至2023年间13751例初次择期全膝关节置换术,其中865例围手术期使用胰高血糖素样肽-1受体激动剂(GLP-1RA),经倾向评分匹配(10:1)选取8650例对照。结果显示GLP-1RA使用在少数族裔和医疗补助保险患者中显著较少;使用GLP-1RA者住院时间更短、家庭出院率更高,90天急诊就诊率更高,但90天再入院和2年翻修率无差异,末次随访全因翻修率显著更低,Kaplan-Meier假体生存无显著差异。
要点
- GLP-1RA使用在黑人、拉丁裔及医疗补助保险患者中显著较少。
- GLP-1RA组住院时间2.1天 vs 对照组2.5天(P<0.001),家庭出院率91.7% vs 84.2%(P<0.001)。
- GLP-1RA组90天急诊就诊率5.9% vs 4.0%(P=0.008),90天再入院和2年翻修率无显著差异。
核心结论
- GLP-1RA在少数族裔和医疗补助保险患者中的使用显著较少。
- 使用GLP-1RA的患者临床结局不劣于对照,且全膝关节置换术前有潜在体重下降作用。
研究设计与样本
- 回顾性综述,纳入2012至2023年间在城市学术医疗系统行初次择期全膝关节置换术且有至少90天随访的13751例,其中865例围手术期使用GLP-1RA。
- 基于性别、年龄、吸烟状态、美国麻醉医师协会分级和体重指数进行10:1倾向评分匹配,创建8650例无GLP-1RA使用的对照队列。
- 证据等级III。
主要发现
- GLP-1RA使用因种族、医疗补助保险、Charlson合并症指数和糖尿病存在情况而显著不同。
- GLP-1RA组住院时间2.1天 vs 对照组2.5天(P<0.001),家庭出院率91.7% vs 84.2%(P<0.001)。
- GLP-1RA组90天急诊就诊率5.9% vs 对照组4.0%(P=0.008),90天再入院率4.3% vs 3.6%(P=0.168),2年翻修率2.3% vs 2.6%(P=0.362)。
- 末次随访全因翻修率GLP-1RA组2.7% vs 对照组3.9%(P=0.034),Kaplan-Meier假体生存无显著差异(P=0.311)。
- 全膝关节置换术前,GLP-1RA组体重指数平均下降0.4,匹配对照组平均增加1.2。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity and diabetes mellitus (DM) pose challenges for patients undergoing total knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as agents for weight and DM management, but they affect multiple organ systems. Outcomes, trends, and demographics for perioperative GLP-1RA use in patients with TKA are not well understood. METHODS: A retrospective review of 13,751 primary, elective TKAs with at least 90 days of follow-up at an urban academic health system between 2012 and 2023 identified 865 patients who had perioperative GLP-1RA use. A 10:1 propensity score match based on sex, age, smoking status, American Society of Anesthesiologists classification, and body mass index created a control cohort of 8,650 TKAs with no GLP-1RA use. RESULTS: The use of GLP-1RAs varied significantly by race, Medicaid insurance, Charlson Comorbidity Index, and presence of DM. Black and Latino patients and those covered by Medicaid were significantly less likely to receive GLP-1RAs. The GLP-1RA group had significantly shorter length of stay (2.1 versus 2.5 days, P < 0.001) and a higher rate of home discharge (91.7 versus 84.2%, P < 0.001). The GLP-1RA users had significantly higher rates of 90-day emergency department visits (5.9 versus 4.0%, P = 0.008), but no differences in 90-day readmissions (4.3 versus 3.6%, P = 0.168) or 2-year revision (2.3 versus 2.6%, P = 0.362) compared to matched controls. The GLP-1RA patients had significantly lower all-cause revision rates at the last follow-up (2.7 versus 3.9%, P = 0.034), but there was no significant difference in Kaplan-Meier implant survival (P = 0.311). Before TKA, GLP-1RA patients had an average decrease in body mass index of 0.4, compared to an average increase of 1.2 for matched controls. CONCLUSIONS: Our results demonstrate that the use of GLP-1RAs is significantly lower for minority patients and those covered by Medicaid. Patients using GLP-1RAs have noninferior clinical outcomes with the potential for weight loss leading up to TKA. LEVEL OF EVIDENCE: III.
引用
- Katzman JL, Haider MA, Cardillo C, et al. Trends, Demographics, and Outcomes for Glucagon-Like Peptide-1 Receptor Agonist Use in Total Knee Arthroplasty: An 11-Year Perspective. J Arthroplasty. 2025. PMID: 40087066. doi:10.1016/j.arth.2025.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。